At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LIMN Liminatus Pharma LLC
Closed 11-03 16:00:00 EST
2.79
+0.27
+10.71%
盘后2.79
+0.000.00%
19:30 EST
High2.83Low2.40Vol44.86K
Open2.63D1 Closing2.52Amplitude16.92%
Mkt Cap3.75MTradable Cap1.62MTotal Shares1.34M
T/O118.29KT/O Rate7.72%Tradable Shares581.43K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Liminatus Pharma Agrees to Sell 260,001 Shares in $650,002.50 Private Placement
Reuters  ·  05:47
Liminatus Pharma Agrees to Sell 260,001 Shares in $650,002.50 Private Placement
Liminatus Pharma regains compliance with Nasdsaq min bid price rule
TIPRANKS  ·  09-29
Liminatus Pharma regains compliance with Nasdsaq min bid price rule
Liminatus Pharma Regains NASDAQ Minimum Bid Price Compliance After Reverse Stock Split
Reuters  ·  09-29
Liminatus Pharma Regains NASDAQ Minimum Bid Price Compliance After Reverse Stock Split
Liminatus Pharma Regains Compliance with NASDAQ Minimum Bid Price Rule
THOMSON REUTERS  ·  09-29
Liminatus Pharma Regains Compliance with NASDAQ Minimum Bid Price Rule
Liminatus Pharma Taps Synex as CRO for Ibc101 Phase 1/2a Study in South Korea
Reuters  ·  08-24
Liminatus Pharma Taps Synex as CRO for Ibc101 Phase 1/2a Study in South Korea
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of Cd19xcd22 Bivalent CAR-T Therapy
THOMSON REUTERS  ·  08-24
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of Cd19xcd22 Bivalent CAR-T Therapy
Liminatus Pharma Reports Reverse Stock Split
MT Newswires Live  ·  08-19
Liminatus Pharma Reports Reverse Stock Split
Liminatus Pharma Sets 1-for-50 Reverse Stock Split Effective Aug. 20
Reuters  ·  08-19
Liminatus Pharma Sets 1-for-50 Reverse Stock Split Effective Aug. 20
Liminatus Pharma, Inc. Announces Reverse Stock Split of Its Common Stock
THOMSON REUTERS  ·  08-19
Liminatus Pharma, Inc. Announces Reverse Stock Split of Its Common Stock
Liminatus Pharma - Announces 1-for-50 Reverse Stock Split
THOMSON REUTERS  ·  08-19
Liminatus Pharma - Announces 1-for-50 Reverse Stock Split
Liminatus Pharma Q2 FY26 Net Loss Widens to $1.41 Million; Operating Loss Widens 23% to $1.38 Million
Reuters  ·  08-15
Liminatus Pharma Q2 FY26 Net Loss Widens to $1.41 Million; Operating Loss Widens 23% to $1.38 Million
Liminatus Pharma (LIMN) Stock Jumps Over 50% on a Listing Update
TIPRANKS  ·  08-14
Liminatus Pharma (LIMN) Stock Jumps Over 50% on a Listing Update
Liminatus Pharma Announces Transfer to NASDAQ Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
THOMSON REUTERS  ·  08-13
Liminatus Pharma Announces Transfer to NASDAQ Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Liminatus Pharma Moves NASDAQ Listing to Capital Market Tier
Reuters  ·  08-13
Liminatus Pharma Moves NASDAQ Listing to Capital Market Tier
Liminatus Pharma Annual Meeting Draws 48.31% of Shares Represented
Reuters  ·  08-05
Liminatus Pharma Annual Meeting Draws 48.31% of Shares Represented
Liminatus Pharma Awaits NASDAQ Ruling After Saying Equity Tops $2.5 Million Threshold
Reuters  ·  07-30
Liminatus Pharma Awaits NASDAQ Ruling After Saying Equity Tops $2.5 Million Threshold
Liminatus Pharma Faces Potential NASDAQ Delisting After Failing $1 Minimum Bid Price Rule
Reuters  ·  07-25
Liminatus Pharma Faces Potential NASDAQ Delisting After Failing $1 Minimum Bid Price Rule
Liminatus Pharma Discloses Ewon Comfortech Initial Beneficial Ownership of 5.5 Million Shares
Reuters  ·  07-07
Liminatus Pharma Discloses Ewon Comfortech Initial Beneficial Ownership of 5.5 Million Shares
Liminatus Pharma Amends Innocsai Merger Terms to Use Non-voting Convertible Preferred Stock
Reuters  ·  07-06
Liminatus Pharma Amends Innocsai Merger Terms to Use Non-voting Convertible Preferred Stock
NASD Most Active Issues
Dow Jones  ·  07-03
NASD Most Active Issues

Introduction

Company Name.
Liminatus Pharma LLC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Iris Acquisition Corp does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was formerly known as Tribe Capital Growth Corp I and changed its name to Iris Acquisition Corp in July 2022. The company was incorporated in 2020 and is based in George Town, Cayman Islands. Iris Acquisition Corp is a subsidiary of Iris Acquisition Holdings LLC.
Issue price:
--